Lupus Nephritis

The Lupus Research Alliance granted its 2023 Global Team Science Award to a multidisciplinary team to study pediatric lupus nephritis, according to a press release.

SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.

The FDA has cleared an investigational new drug application for AlloNK in combination with rituximab to treat systemic lupus erythematosus in patients with active lupus nephritis, according to a press release from Artiva Biotherapeutics.

The FDA has granted fast-track designation to Kyverna’s KYV-101, a novel anti-CD19 chimeric antigen receptor T-cell therapy for patients with refractory lupus nephritis, according to a company press release.

The Lupus Research Alliance, alongside its research affiliate Lupus Therapeutics, have announced the launch of what would be the largest prospective observational study into lupus, as well as a new patient registry and data resource.

DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.

Health care professionals around the world are reporting that the COVID-19 pandemic has prevented patients with systemic lupus erythematosus from receiving optimal care, resulting in increased risk for organ damage, according to a survey.

PHILADELPHIA — Half of patients with systemic lupus erythematosus and new-onset, low-grade proteinuria progress to clinical proteinuria within 2 years, according to results of a study presented at ACR Convergence 2022.